News | November 16, 2024
IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Construction of the plant will commence in 2025 with first production expected to be in 2027
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Subscribe To Our Newsletter & Stay Updated
